Valeant Climbs After Lenders Agree to Amend Credit Line: Chart

Valeant Pharmaceuticals International Inc. rose as much as 5.1 percent in early trading Thursday to touch its highest level in more than three months and add to a week of gains. The drugmaker, tackling a $30 billion debt load, received support from a majority of lenders to loosen terms on its credit agreement.

    Before it's here, it's on the Bloomberg Terminal.